



CFO

Michael Corry

Friday 25th November 2016

Financial Overview

	2016	2015
For period ending 30 June		
Loss for the year	\$1.3m	\$1.4m
Cash at bank	\$1.0m	\$0.3m
Net liabilities	\$0.7m	\$0.2m
Shares on issue	223.8m	207.0m
Share capital	\$49.4m	\$48.7m
Current		
Cash at bank	\$1.0m	
Shares on issue	311.4m	



CEO's Address

Archie Fraser

Friday 25th November 2016

Introduction

- Carl Zeiss Meditec
- ViewnVivo
- New Market Opportunities
- Summary



Carl Zeiss Meditec Partnership - Microsurgery

- Esteemed in optical imaging
- Market leader in neurosurgical visualisation

[Medical Technology](#) [Products & Solutions](#) [Services](#) [Media & News](#) [About Us](#)

[Home](#) / [Products & Solutions](#) / [Neurosurgery](#)



The moment you expand the surgical boundaries beyond what seems possible.
This is the moment we work for.

// MICROSURGERY
MADE BY ZEISS

Carl Zeiss Meditec

- Carl Zeiss Meditec are a respected global player with market leadership in the Medical Technology space
 - Annual Revenues of greater than Euro 1billion
 - Significant revenue coverage in all global markets;
 - EMEA 32.9%
 - Americas 32.2%
 - APAC 34.9%
 - With subsidiaries in USA, UK, Spain, France, Germany, Japan and Turkey
 - Research centres in India and China.
 - Carl Zeiss Meditec can be the perfect take-to-market partner for Optiscan technology and for the future growth for Optiscan revenues

Carl Zeiss Meditec

- Background
 - Carl Zeiss Meditec and Optiscan have a collaboration relationship which dates back more than 10 years
 - In the past 18 months this relationship has accelerated with the past 6 months seeing significant progress made on a specific collaboration project targeted at the Neuro market
 - Carl Zeiss Meditec are a significant global player and highly respected in the medical optical surgery space across a range of disciplines
 - The Carl Zeiss investment is now significant, both in financial terms and senior personnel and the overall resources working on this collaboration project

Carl Zeiss Meditec

- Congress of Neurological Surgeons September 2016 (CNS San Diego)



**Congress of
Neurological
Surgeons**

The global leader in
neurosurgical education

- The Chairman (Alan Hoffman), Director (Peter Francis) and the CEO (Archie Fraser) attended the CNS 2016 in San Diego to meet with Carl Zeiss Senior Management
- At CNS the joint collaboration project prototype and product application concept was discussed with a select number of preeminent medical professionals selected by Carl Zeiss
- Feedback for the various potential applications was sought and recorded by Carl Zeiss
- Carl Zeiss have indicated that Initial feedback from CNS was positive as to the potential applications for future clinical use of the Optiscan technology

Carl Zeiss Meditec

- Visit to Carl Zeiss Meditec Headquarters - November 2016 (Oberkochen)
 - November 2016 Optiscan CEO - Archie Fraser and General Manager Preclinical Research Products - Andrew Froude met with Senior Management of Carl Zeiss Meditec to discuss the ongoing relationship and specifically;
 - existing collaboration project,
 - long term potential strategy and;
 - the future and potential for joint opportunities in Clinical and Preclinical markets
 - Engagement will continue to agree which markets have the greatest potential for further collaboration and mutual commercialisation for Optiscan and Carl Zeiss Meditec



Carl Zeiss Meditec

- **Collaboration Project Status**
 - The collaboration project is at the point where Production Equivalent Systems will be supplied to Carl Zeiss in December 2016 for testing and validation over the coming months
 - Subject to testing approvals Optiscan expects to deliver a number of additional systems to Carl Zeiss over the next 12 months
 - Testing and approvals for CE, FDA and the customised sterile sheath will progress over the next 6-9 months
 - Launch dates are still subject to the successful and satisfactory testing and timing the of regulatory medical approvals for clinical equipment, systems and accessories in the various jurisdictions



Carl Zeiss Meditec

- Future Outlook
 - Carl Zeiss Meditec are potentially the perfect global partner for Optiscan
 - The Carl Zeiss Meditec relationship is on track to be a commercially significant and a long term partnership
 - The existing collaboration project has to be successfully taken to market, proven and accepted by clinicians
 - There is potential to expand this relationship into other disciplines – following the success of the current collaboration project
 - We will continue to work with Carl Zeiss Senior Management and explore potential commercial strategies and further applications for the Optiscan technology over the next 12 months



**General Manger
Preclinical Research Products**

Andrew Froude

Friday 25th November 2016



View*n*VIVO

Optiscan's next generation of
incredible imaging capability and
flexibility for Preclinical Research

Andrew Froude
General Manager
Preclinical Research Products

ViewnVIVO

- Overview
- Target Markets and Competition
- Product Launch
- Market Engagement and Approach

ViewnVIVO Overview

- Next Generation (Latest Technology)
- Miniaturised Fluorescence Endomicroscope
 - Handheld Probe
- For use in Preclinical (Animal) Research
- Of Living Tissue within a Living Animal
 - Although can be used Ex Vivo
- To Directly Observe ‘Systems Biology’
 - Complex Interactions
- In Submicron Detail



Viewn^{VIVO} Main Focus

- Stunning Image Quality
- Full-screen Output
- Miniaturised – Without Sacrificing Image Quality
- Real-time In Vivo (and Ex Vivo)
- System Flexibility and Usability
- No Probe Change Required
- ‘Take Imaging to the Model’ at any angle of approach
 - not adapt model for imaging
- No Calibration Required
- No Dedicated Technician or Facility Required


Viewn^{VIVO} Target Markets

- Animal Research Laboratories
- Universities
- Hospitals (that conduct Research)
- Pharmaceutical Companies


ViewnVIVO Competition

Primary: Miniaturised Confocal Systems

- Technology: Bundled Fibre
- Advantages over Bundled Fibre
 - Image Quality (estimated to be >30x)
 - Field of View
 - Imaging Depth
 - Lower Laser Power and Greater Imaging Sensitivity
 - Single Probe with same sensitivity, field of view and imaging depth



Bundled Fibre




Optiscan Point Scanning

ViewnVIVO Competition

Secondary: Fixed/Benchttop Microscopes

- Traditional Suppliers
- Advantages over Benchttop/Fixed Microscopes
 - Flexibility
 - Take Imaging to Animal Model
 - Reduced Terminal procedures
 - Anyone can use it
 - No Dedicated Technician
 - No Dedicated Facility
 - No Calibration
 - Reduced Investment



Viewn^{VIVO} The Name

- Reflect Product and Application
- Easy to Understand by virtually anyone
- Not an Acronym
- Not already Trademarked or Registered
- Must have access to Primary and Secondary Domains (website addresses) globally
- Shortlisted names
- Extensive Search conducted

Viewn^{VIVO}

View, See, Observe

In, Variable

Living

ViewnVIVO Launch

- Announced / Launched: 22nd November 2016
- Dedicated Website: viewnvivo.com



The screenshot shows the ViewnVivo website homepage. At the top, there is a navigation bar with the ViewnVivo logo on the left and search, lock, and user icons on the right. Below the navigation bar is a main content area featuring a large, colorful fluorescence microscopy image of rat colonic mucosa. The image is labeled "Rat Colonic Mucosa" and includes the text "Labelled with topical Acriflavine" and "Image colourised using ImageJ". A scale bar indicates "Scale: 100 microns (i.e. 0.1mm)". The ViewnVivo logo is also present in the bottom right corner of the image. Below the image, there is a text block that reads: "ViewnVivo is a miniaturised fluorescence endomicroscope platform that brings the next generation of Optiscan's incredible imaging capability and flexibility to Preclinical Research." The OptiScan logo is visible in the bottom left corner of the screenshot.



ViewnVivo Collateral


- Brochure
- Aim: Contact Optiscan



Download Brochure



ViewnVIVO Collateral



ViewnVIVO
Superior Optics

Capture High Resolution real-time *in vivo* images with submicron detail and view them in stunning quality for faster Preclinical Research insights.

ViewnVIVO Overview

Validated Capability

ViewnVIVO is a miniaturised fluorescence endomicroscope platform that brings the next generation of Optiscan's incredible imaging capability and flexibility to Preclinical Research.

Stunning Image Quality

See real-time submicron resolution images in full-screen glory. Optiscan's patented imaging technology and variably adjustable imaging depth allows the investigation and capture of detail not possible from any other single miniaturised confocal microscope probe.

Miniaturised

Miniaturised no longer means compromise. Not only does the ViewnVIVO platform capture images comparable to those previously only possible from larger and more expensive fixed/bench mounted microscopes, it gives you the flexibility to view cellular and sub-cellular structures *in vivo* that can quickly take your research to another level.



Real-time In Vivo Insight

As someone who values the benefit of detailed insight you will appreciate the ability to unlock the ultimate and most direct observations of systems biology *in vivo*. No longer do you need to try to observe living tissue in an unnatural manner. With ViewnVIVO not only can you see it in its natural state but you can enable longitudinal studies and keyhole procedures whilst reducing terminal procedures.

Flexibility

Don't let inflexible bench mounted microscopy be a limiting factor. The flexibility of a miniaturised probe enables investigation not possible through fixed benchtop microscopes. ViewnVIVO lets you take the miniaturised probe to your animal model and position it in any angle of approach to allow you to interrogate the structures of interest, *in vivo*.

No Dedicated Technician or Facility Required

ViewnVIVO delivers maximum flexibility in a platform so simple and small that it doesn't require a dedicated technician or facility, meaning it can be used by virtually anyone and still capture unbelievable images that will validate your investigations.

It is all about the Captured Image

ViewnVIVO Collateral

ViewnVIVO Puts you in Control

Research: "the systematic investigation into and study of materials and sources in order to establish facts and reach new conclusions." Source Google

No Probe Change Required


You won't need to change probes within a procedure, although you can change the probe form factor to suit the investigation without the need to restart the system. **Unlike other technologies, with ViewnVivo you can dynamically adjust imaging parameters using a single probe** enabling uninterrupted imaging.

Multiple Probe Form Factors

Choose the Probe form factor that suits your application without sacrificing imaging quality, sensitivity or imaging depth. Each probe is fitted with a strong umbilical cable to reduce the chance of damage.


Available sizes:
 46mm x 4mm (Optional)
 66mm x 4mm (Standard)
 300mm x 4mm (Optional Laparoscope)

(Please contact Optiscan for other options)



Any Angle of Approach

Whether you hold the probe in your hand or utilise the adjustable holder and micro positioners with the animal stage, you can approach your animal model at any angle to optimise imaging. Try doing that on a Benchtop microscope.



ViewnVivo gives you the control and flexibility you need to get to the highest quality outcome as quickly as you can, and before someone else does.

Low Level Laser Power

Obtain the optimal image through variable laser power and automatic brightness control, without bleaching your specimen.

Full Screen Output

High Resolution 1080p output at variable aspect ratios.

Field of View

A wide field of view at full resolution (475µm x 475µm), and selectable resolution lossless zoom, combined with benchmark optical resolution within a single probe without compromise.

Scan Speed


Capture just the right amount of detail. Scan at the speed required for the task at hand and adjust as required up to 6 fps.

On-demand and Automated Image Capture

Never miss an Image. Capture Images and their associated meta-data on-demand even if your hands are full, or automatically as a series of image depths (z-stack). Images can even be captured retrospectively from the live image stream through the 'roll-back' functionality.

3D Visualisation

Building and analysing 3D Visualisations starts with non-proprietary images and meta-data captured through ViewnVivo's superior optics and precise imaging depth control and processed by your choice of image Processing Software (Imaged included).



Precise Depth Control

Interactive and continuously variable depth control (z-axis) 0 - 400µm **without the need to change the probe**, this provides precise optical sectioning and enables the isolation and capture of the structures and detectable events you need. Simply position the probe once and capture all of the images you need.

Flexible Control

Optiscan understands that in a real-life situation you need flexibility. Users can choose to interact with the system in multiple ways to support different workflows and protocols depending on their preference and the current interrogation. Using System control buttons, Mouse, Keyboard, Footswitch or an optional Touch Screen you can change settings and capture the optimal images you need, even if your hands are full.

Productive in minutes

To get the most out of your ViewnVivo you don't need a dedicated technician, therefore enabling the broadest and most flexible use to achieve outcomes quickly and at a lower cost. **The self-calibrating system and probes let you turn it on and use it.**


Filter Selection

Change Filters on the fly to pinpoint and highlight the colour range of interest. With 8 standard filters to suit the most common fluorescent contrast agents and molecular markers, and provision for up to 4 custom filters, ViewnVivo enables your research protocol.

ViewnVIVO Collateral

Optical Sectioning

Interrogate and analyse tissue as a truly 3D microscopic volume, without moving or changing the probe.



Simply position the probe once and through the use of the interactive and continuously variable depth control (z-axis) you can capture all of the images you need as Optical sections and generate 3D visualisations that allow you to study and analyse your discovery.



ViewnVivo B30 Specification Summary


Imaging Resolution:	< 0.5µm lateral; <4.5µm axial
Imaging Depth:	0 - 400µm (without moving or changing the probe)
Z-Step:	3µm (precision 1µm)
Field of View:	475µm x 475µm at full resolution plus zoom
Wavelength:	488nm
Probe Outer Diameter:	4mm
Standard Probe Length:	66mm (straight rigid) – others available
Probe Cable Length:	1.500mm
Filter Wheel:	12 Position (8 Standard filters included)
Image Capture:	Single Frames, Z-Stacks and [retrospective] Roll-back
Image Output:	TIFF and Multi-page TIFF with embedded Meta-data

Canine Small Intestine
Image courtesy of Researchers at University of Melbourne,
Faculty of Veterinary and Agricultural Sciences.

ViewnVIVO

Patented Technology

Optiscan's patented Point Scanning Confocal technology provide's far superior image quality than 'Bundled Fibre' technology (the alternative miniaturised technology). As can be seen from the example images below Bundled Fibre technology captures an image that resembles looking through the door of a microwave oven, i.e. it is missing information, whereas Optiscan's Point Scanning Confocal technology captures a full and complete raw image.



You can't create what does not exist. Information missing in a raw captured image cannot be created with image processing. Don't settle for half the picture; use ViewnVivo.

InVivo imaging accelerates your reasearch

Now you can have the best of both worlds; stunning real-time in vivo images and the flexibility enabled by miniaturisation. ViewnVivo enables endless possibility by unlocking the ultimate and most direct observations of system biology to help you reach your objective quickly.

Open your world of possibility with ViewnVivo

Don't let your scientific endeavours fall behind, or let someone else be your defining factor. Create your own legacy starting today by seeing how ViewnVivo can take you there. Contact Optiscan today

More information

For more information, including Example Images, Application Notes and Detailed Specifications, simply go to: www.viewnvivo.com



Contact
Optiscan now.



More
Information.

100 microns


Please note: Printed resolution does not equal the real image quality. See it for yourself.



ViewnVivo Collateral



Download Brochure



ViewnVIVO Market Engagement

- Existing Customers
- Referrals
- Existing Partners
- Existing Distributors
- Market Awareness
 - Association Sponsorship
 - Other Marketing Events and Industry Trade-shows (TBA)

ViewnVIVO Approach

- Focus, Keep it Simple and Logical
 - In a complex market and technical environment
 - One thing at a time
 - Deliver
- Three Primary Objectives (barriers to remove)
 - Let customers know it exists
 - Create Product
 - Make it available to buy (Launch)
 - Refine Product
 - Commercially viable
 - Affordable
 - Enable Interacting with Optiscan
 - Who to contact
 - How to contact
 - Find Information
 - Get Assistance
 - Place, Process and Deliver an Order



View*n*Vivo

Commercialising the Worlds Leading Technology

Thank you

New Market Opportunities





New Market Opportunities

- **Flexible Endoscope Applications**
 - Gastro Intestinal (GI)
- **Women's Health**
 - Endometriosis
 - Ovarian cancer

12 - 24 Month Outlook

A hand holding a white marker is writing the text "WHAT'S NEXT?" in a bold, black, hand-drawn font on a white surface. A thick black underline is drawn beneath the text. The background of the whiteboard area is white with faint, light blue circular patterns.

WHAT'S NEXT?



12 - 24 Month Outlook

- Carl Zeiss Meditec collaboration project
- Expand the Carl Zeiss Partnership into other fields
- *ViewnVivo* sales and revenue generation
- Additional commercial partnerships in GI and Women's Health
- Develop commercial Flexible Endoscope applications



Formal Business

Alan Hoffman

Friday 25th November 2016



Accounts for 2015/16

To receive and consider the Financial Report, Directors' Report and the Auditor's Report for the financial year ended 30 June 2016



Proxy Snapshot

Optiscan Annual General Meeting (25/11/2016) Vote Totals - Snap Shot (Resolution 2A)

Securities on Issue	311,428,800
Valid Securities Voted - Shares	75,481,853
Valid Securities Voted - %	24.24

Source: Computershare



Non-Binding Resolution 1

“That the Remuneration Report included in the Annual Report for the year ended 30 June 2016 be adopted.”

Proxy Summary

Vote Type	Shares	%
For	55,627,219	96.27%
Against	2,155,261	3.73%
Abstain	253,164	n/a
Excluded	17,668,445	n/a



Ordinary Resolution 2A

“That Mr Alan Hoffman, a director appointed to fill a casual vacancy on 3 May 2016 retiring in accordance with clause 55.2 of the Company's Constitution, being eligible and having signified his candidature for the office, be re-elected a director of the Company.”

Proxy Summary

Vote Type	Shares	%
For	73,970,441	98.14%
Against	1,402,248	1.86%
Abstain	331,850	n/a
Excluded	0	n/a



Ordinary Resolution 2B

“That Mr Ian Mann, a director appointed to fill a casual vacancy on 9 December 2015 retiring in accordance with clause 55.2 of the Company's Constitution, being eligible and having signified his candidature for the office, be re-elected a director of the Company.”

Proxy Summary

Vote Type	Shares	%
For	56,427,163	97.79%
Against	1,277,081	2.21%
Abstain	18,000,295	n/a
Excluded	0	n/a



Ordinary Resolution 2C

“That Mr Peter Francis, a director appointed to fill a casual vacancy on 3 May 2016 retiring in accordance with clause 55.2 of the Company's Constitution, being eligible and having signified his candidature for the office, be re-elected a director of the Company.”

Proxy Summary

Vote Type	Shares	%
For	74,205,365	98.39%
Against	1,217,212	1.61%
Abstain	281,962	n/a
Excluded	0	n/a



Ordinary Resolution 2D

“That Dr Ian Griffiths, a director appointed to fill a casual vacancy on 3 May 2016 retiring in accordance with clause 55.2 of the Company's Constitution, being eligible and having signified his candidature for the office, be re-elected a director of the Company.”

Proxy Summary

Vote Type	Shares	%
For	74,159,477	98.39%
Against	1,213,212	1.61%
Abstain	331,850	n/a
Excluded	0	n/a



Ordinary Resolution 3A

“That, for the purposes of Australian Securities Exchange Listing Rule 7.4, shareholders ratify the prior issue of issue of 3,000,000 ordinary fully paid shares on the dates and at the prices set out in the Explanatory Notes accompanying this Notice of Meeting.”

Proxy Summary

Vote Type	Shares	%
For	71,699,420	97.24%
Against	2,038,451	2.76%
Abstain	366,362	n/a
Excluded	1,600,000	n/a



Ordinary Resolution 3B

“That, for the purposes of Australian Securities Exchange Listing Rule 7.4, shareholders ratify the prior issue of issue of 29,980,000 ordinary fully paid shares on the dates and at the prices set out in the Explanatory Notes accompanying this Notice of Meeting.”

Proxy Summary

Vote Type	Shares	%
For	46,012,854	95.62%
Against	2,108,090	4.38%
Abstain	130,185	n/a
Excluded	27,453,410	n/a



Ordinary Resolution 4

“That, for the purposes of Australian Securities Exchange Listing Rule 10.11, and as consideration for the repayment of a loan to the Company in the amount of \$600,000, a total of 24,000,000 shares be issued to Ibsen Pty Ltd <Narula Family Set No 3 a/c>, an entity associated with Director Mr Ian Mann.”

Proxy Summary

Vote Type	Shares	%
For	49,565,751	95.88%
Against	2,128,342	4.12%
Abstain	24,010,140	n/a
Excluded	0	n/a



Ordinary Resolution 5

“That, for the purposes of Australian Securities Exchange Listing Rule 7.1, the issuance of 7,500,000 unlisted options to Chief Executive Officer Mr Archie Fraser, having the terms set out in the Explanatory Notes to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	72,119,642	95.91%
Against	3,073,489	4.09%
Abstain	511,408	n/a
Excluded	0	n/a



Ordinary Resolution 6A

“That, for the purpose of ASX Listing Rule 10.11 and for all other purposes, the issuance of 3,000,000 unlisted options to Alan Hoffman (or his nominee) on the terms and conditions set out in the Explanatory Memorandum to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	72,631,411	96.34%
Against	2,762,933	3.66%
Abstain	310,195	n/a
Excluded	0	n/a



Ordinary Resolution 6B

“That, for the purpose of ASX Listing Rule 10.11 and for all other purposes, the issuance of 3,000,000 unlisted options to Ian Mann (or his nominee) on the terms and conditions set out in the Explanatory Memorandum to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	54,966,640	95.22%
Against	2,759,259	4.78%
Abstain	17,978,640	n/a
Excluded	0	n/a



Ordinary Resolution 6C

“That, for the purpose of ASX Listing Rule 10.11 and for all other purposes, the issuance of 3,000,000 unlisted options to Peter Francis (or his nominee) on the terms and conditions set out in the Explanatory Memorandum to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	72,632,585	96.34%
Against	2,761,759	3.66%
Abstain	310,195	n/a
Excluded	0	n/a



Ordinary Resolution 6D

“That, for the purpose of ASX Listing Rule 10.11 and for all other purposes, the issuance of 3,000,000 unlisted options to Ian Griffiths (or his nominee) on the terms and conditions set out in the Explanatory Memorandum to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	73,131,192	97.00%
Against	2,263,152	3.00%
Abstain	310,195	n/a
Excluded	0	n/a



Ordinary Resolution 7

“That, for the purposes of Australian Securities Exchange Listing Rule 7.1, the issuance of 5,000,000 options to Life Sciences Pty Ltd, having the terms set out in the Explanatory Notes to this Notice of Meeting, is approved.”

Proxy Summary

Vote Type	Shares	%
For	68,463,969	90.67%
Against	7,047,959	9.33%
Abstain	192,611	n/a
Excluded	0	n/a



Special Resolution 8

“That for the purposes of ASX Listing Rule 7.1A, shareholders approve the Company having the capacity to issue fully paid ordinary shares in the capital of the Company up to the maximum number permitted under ASX Listing Rule 7.1A.2 at an issue price which is not less than 75% of the volume weighted average market (closing) price of the Company’s ordinary shares calculated over the last fifteen (15) days on which trades of the Company’s ordinary shares were recorded on ASX immediately before the date on which the issue price is agreed or the date the issue is made as described in the Explanatory Memorandum which accompanied and forms part of this Notice of Meeting.”

Proxy Summary

Vote Type	Shares	%
For	66,514,493	96.11%
Against	2,694,155	3.89%
Abstain	6,495,891	n/a
Excluded	0	n/a



Any Other Questions

Alan Hoffman

Friday 25th November 2016



OptiScan Imaging Limited

Annual General Meeting

Friday 25th November 2016